Next-generation tuberculosis vaccine discovery

Charlotte Barker, Editor, Vaccine Insights, speaks to Gillian Beamer, Adjunct Associate Professor and Staff Scientist III, Texas Biomedical Research Institute (Texas Biomed) & Emily Voigt, Principal Scientist at Access to Advanced Health Institute (AAHI)

Gillian Beamer, VMD, PhD, DACVP, is a veterinary pathologist and research scientist studying tuberculosis. She is an Adjunct Associate Professor and Independent Staff Scientist at Texas Biomed. Dr Beamer has about 20 years experience in veterinary medicine, pathology and scientific research. She is a Board Certified Diplomate in the American College of Veterinary Pathologists, having completed a residency in veterinary anatomic pathology at The Ohio State University. She earned her VMD from University of Pennsylvania in 2000 and her PhD from The Ohio State University in 2009. She joined Texas Biomed in 2022.

Emily Voigt is a scientist with 13 years of experience in innate and vaccine immunology. She received her BSc in Chemical Engineering from Kansas State University and her PhD in Chemical and Biological Engineering from University of Wisconsin-Madison. She completed her postdoctoral fellowship at the Mayo Clinic’s Vaccine Research Group where she gained experience in conducting, analyzing, and publishing clinical studies of human and mouse immune responses to a variety of vaccines. Dr Voigt joined AAHI in 2018 where her extensive experience in RNA vaccine design and synthesis, viral immunology, and vaccine immunogenicity drives AAHI’s RNA platform innovation to enable RNA vaccines and immunotherapies to be equitably accessible to all areas of the world, including resource-limited areas.

The US National Institute of Allergy and Infectious Diseases recently awarded Texas Biomedical Research Institute (Texas Biomed) and the Access to Advanced Health Institute (AAHI), a joint US $ 3.5 million, 5 year Innovation for Tuberculosis Vaccine Discovery grant. We caught up with two of the scientists involved in the project.

Please enter your email to access content Read now